A clinical trial to study the effect of trial drug MILAGU LEGIYAM(Internal0,SEERAGA THYLAM(External)on Cegana vatham(Cervical spondylosis)

An Open Clinical Study to evaluate the clinical efficacy of siddha sasthric formulation "MILAGU LEGIYAM"(Internal)"SEERAGA THYLAM"(External) for the treatment of CEGANAVATHAM.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/012135

Enrollment

Registered

2018-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- neck pain , neck stiffness , radiating pain towards upper limbs , guidiness , head ache

Interventions

Intervention1: Milagu legium(Internal)6gram bd Seeraga thylam(External)30 ml: 6gram bd (Internal) 30Ml Thylam(External) for 48 days Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age:20-65yrs 2.Sex:both male and female 3.Stiffness of neck 4.Pain Radiating towards to the upper limbs 5.With or with out numbness in the upper limbs 6.Guidiness 7.willing for stay in IPD or willing to attend 8.OPD willing for doing laboratory investication and X-ray imaging

Exclusion criteria

Exclusion criteria: 1.Spina bifida 2.Cervical rib 3.Liver disease 4.Pregnancy and Lactation 5.Ankylosing spondylosis 6.Renal disease 7.Congenital anomalies of spine 8.Patient with any other systemic illness 9.Recent dislocation / Trauma

Design outcomes

Primary

Measure	Time frame
Reduce pain In Cervical Region and Upper Limp Reduce Stiffness and Spasm of NeckTimepoint: 48 days	—

Secondary

Measure	Time frame
Evaluation of Siddha Diagnostic ParametersTimepoint: 48 days	—

Countries

India

Contacts

Public ContactDr D subathra

Government siddha medical college , palayamkottai

dr.ahmed63@gmail.com8428466943

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026